实体瘤免疫治疗中的细胞因子组合：综述
Cytokine combinations in immunotherapy for solid tumors: a review.
作者信息
Heaton K M, Grimm E A
机构信息
Department of General Surgery and Tumor Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
出版信息
Cancer Immunol Immunother. 1993 Sep;37(4):213-9. doi: 10.1007/BF01518513.
Abstract
The use of cytokines alone or in combination with other cytokines or cytotoxic drugs has had a profound effect upon widely metastatic disease in many cases. However, despite the encouraging results in early trials, there is much room for improvement. Few responses to these combinations are complete, and toxicity has in some cases been quite severe. Changes in dose, route, or schedule of administration of the drugs, or the development of cytokine analogs may lead to more efficacious and less toxic regimens. In addition, new cytokines such as interleukin(IL)-7 and IL-12 are currently under investigation for potential use in future immunotherapy trials. These prospects and the use of cytokine combinations are promising advances in the treatment of human cancer.
摘要
单独使用细胞因子或与其他细胞因子或细胞毒性药物联合使用，在许多情况下已对广泛转移的疾病产生了深远影响。然而，尽管早期试验结果令人鼓舞，但仍有很大的改进空间。这些联合用药很少能产生完全缓解，而且在某些情况下毒性相当严重。改变药物的剂量、给药途径或给药方案，或开发细胞因子类似物，可能会产生更有效且毒性更小的治疗方案。此外，诸如白细胞介素（IL）-7和IL-12等新型细胞因子目前正在研究中，有望用于未来的免疫治疗试验。这些前景以及细胞因子联合用药的应用，是人类癌症治疗中很有前景的进展。
相似文献
1
Cytokine combinations in immunotherapy for solid tumors: a review.实体瘤免疫治疗中的细胞因子组合：综述
Cancer Immunol Immunother. 1993 Sep;37(4):213-9. doi: 10.1007/BF01518513.
2
Cytokine-based therapy and biochemotherapy for advanced melanoma.基于细胞因子的疗法及晚期黑色素瘤的生物化疗
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2353s-2358s. doi: 10.1158/1078-0432.CCR-05-2503.
3
Interleukin-2: solid-tumor therapy.白细胞介素-2：实体瘤治疗
Oncology. 1994 Mar-Apr;51(2):154-69. doi: 10.1159/000227330.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.用于实体瘤免疫治疗的细胞因子、趋化因子和共刺激融合蛋白。
Handb Exp Pharmacol. 2008(181):291-328. doi: 10.1007/978-3-540-73259-4_13.
6
Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10.基于细胞因子的癌症免疫治疗：IL-10 的挑战与机遇。
Anticancer Res. 2021 Jul;41(7):3247-3252. doi: 10.21873/anticanres.15110. Epub 2021 Jul 5.
7
Second- and third-generation drugs for immuno-oncology treatment-The more the better?免疫肿瘤治疗的第二代和第三代药物——越多越好？
Eur J Cancer. 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10.
8
Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.转移性肾细胞癌免疫治疗的预后和预测因素
Crit Rev Oncol Hematol. 2002 Mar;41(3):327-34. doi: 10.1016/s1040-8428(01)00173-1.
9
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.2006年及以后细胞因子疗法在转移性肾细胞癌治疗中的作用
J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638.
10
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发：现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
引用本文的文献
1
Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.溶瘤病毒靶向递送 IL-12 佐剂免疫疗法。
Adv Exp Med Biol. 2021;1290:67-80. doi: 10.1007/978-3-030-55617-4_4.
2
Cytokine-mediated communication: a quantitative appraisal of immune complexity.细胞因子介导的通讯：对免疫复杂性的定量评估。
Nat Rev Immunol. 2019 Apr;19(4):205-217. doi: 10.1038/s41577-019-0131-x.
3
[Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy].[在全身免疫化疗失败后，通过吸入白细胞介素-2治疗实现肾细胞癌肺转移的完全缓解]
Urologe A. 2004 Oct;43(10):1271-4. doi: 10.1007/s00120-004-0669-4.
4
Immunostimulatory DNA sequences and cancer therapy.免疫刺激DNA序列与癌症治疗
Springer Semin Immunopathol. 2000;22(1-2):107-16. doi: 10.1007/s002810000022.
5
The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.细胞毒性T淋巴细胞在肿瘤预防和免疫监视中的作用——来自正常和免疫缺陷小鼠的经验教训。
Med Oncol. 1999 Dec;16(4):223-38. doi: 10.1007/BF02785868.
6
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.白细胞介素-2可增强基于重组痘病毒的疫苗在治疗已形成的肺转移瘤中的功能。
J Immunol. 1995 May 15;154(10):5282-92.
7
Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen.用重组猴病毒40大肿瘤抗原免疫小鼠后诱导产生的淋巴因子检测。
Cancer Immunol Immunother. 1995 Mar;40(3):206-11. doi: 10.1007/BF01517353.
本文引用的文献
1
Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor.用对中等亲和力白细胞介素2（IL-2）受体具有特异性的IL-2类似物刺激人外周血单个核细胞后对淋巴因子激活的杀伤作用的表征
Cell Immunol. 1993 Mar;147(1):167-79. doi: 10.1006/cimm.1993.1057.
2
Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.白细胞介素-2和干扰素-α-2a门诊治疗转移性肾细胞癌。
J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):122-9. doi: 10.1097/00002371-199302000-00007.
3
A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma.一项关于人白细胞介素-2与α-2a干扰素联合治疗播散性恶性黑色素瘤患者的II期试验。
J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):117-21. doi: 10.1097/00002371-199302000-00006.
4
On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.白细胞介素-2与白细胞介素-10在淋巴因子激活的杀伤细胞活性产生中的相对作用
Cell Immunol. 1993 Feb;146(2):391-405. doi: 10.1006/cimm.1993.1035.
5
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.淋巴因子激活的杀伤细胞现象。白细胞介素2激活的自体人外周血淋巴细胞对天然杀伤抗性新鲜实体瘤细胞的杀伤作用。
J Exp Med. 1982 Jun 1;155(6):1823-41. doi: 10.1084/jem.155.6.1823.
6
Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.人重组β-干扰素丝氨酸在肾细胞癌患者中的I/II期试验。
Cancer Res. 1986 Oct;46(10):5364-7.
7
Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.用聚乙二醇对重组白细胞介素2进行化学修饰可增强其在小鼠Meth A肉瘤模型中的效力。
Proc Natl Acad Sci U S A. 1987 Mar;84(6):1487-91. doi: 10.1073/pnas.84.6.1487.
8
9
10
Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.肿瘤坏死因子与白细胞介素2在激活人细胞毒性淋巴细胞中的协同作用：肿瘤坏死因子α和白细胞介素2对人淋巴因子激活的杀伤细胞细胞毒性产生的影响。
Cancer Res. 1988 Feb 15;48(4):788-92.
Zotero 插件